FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382777498> ?p ?o ?g. }

• W4382777498 endingPage "3955" @default.
• W4382777498 startingPage "3937" @default.
• W4382777498 abstract "In the European Union (EU), the indication for the antifibrotic pirfenidone prior to April 2023 did not include patients with advanced idiopathic pulmonary fibrosis (IPF). This analysis compared the efficacy and safety of pirfenidone in advanced IPF versus non-advanced IPF. Data were included from the following studies of pirfenidone: ASCEND (NCT01366209); CAPACITY (004 [NCT00287716] and 006 [NCT00287729]); RECAP (NCT00662038; advanced IPF defined as percent predicted forced vital capacity [%FVC] < 50% and/or percent predicted carbon monoxide diffusing capacity [%DLco] < 35% at baseline); PASSPORT (NCT02699879; advanced IPF defined as baseline %FVC < 50%); and SP-IPF (NCT02951429; patients with advanced IPF [defined as %DLco ≤ 40% at screening] at risk of group 3 pulmonary hypertension). In the pooled ASCEND/CAPACITY studies, the annual mean rate of FVC decline from baseline to Week 52 was significantly lower for pirfenidone versus placebo in advanced (p = 0.0035) and non-advanced IPF (p = 0.0001). Rate of all-cause mortality over 52 weeks was numerically lower for pirfenidone versus placebo in advanced and non-advanced IPF. In RECAP, the mean annual rate of FVC decline from baseline to Week 180 of pirfenidone treatment was similar in patients with advanced (− 141.5 mL) and non-advanced IPF (− 153.5 mL). In SP-IPF, the mean annual rate of FVC decline and rate of all-cause mortality from baseline to Week 52 in patients treated with placebo + pirfenidone were − 93.0 mL and 20.2%, respectively. No new safety signals were identified, and the safety profile of pirfenidone in patients with advanced IPF was generally consistent with that of non-advanced IPF. These results highlight the benefit of pirfenidone treatment in patients with advanced and non-advanced IPF. As such, the indication for pirfenidone in the EU has now been updated to include the treatment of adult patients with advanced IPF. ASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429)." @default.
• W4382777498 created "2023-07-02" @default.
• W4382777498 creator A5019246724 @default.
• W4382777498 creator A5027575751 @default.
• W4382777498 creator A5030667668 @default.
• W4382777498 creator A5035492584 @default.
• W4382777498 creator A5037134872 @default.
• W4382777498 creator A5044010028 @default.
• W4382777498 creator A5044597853 @default.
• W4382777498 creator A5052485494 @default.
• W4382777498 creator A5079519206 @default.
• W4382777498 creator A5087322552 @default.
• W4382777498 creator A5090203143 @default.
• W4382777498 date "2023-06-30" @default.
• W4382777498 modified "2023-10-08" @default.
• W4382777498 title "Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies" @default.
• W4382777498 cites W2004697839 @default.
• W4382777498 cites W2037681111 @default.
• W4382777498 cites W2057292199 @default.
• W4382777498 cites W2100059970 @default.
• W4382777498 cites W2108226118 @default.
• W4382777498 cites W2117488044 @default.
• W4382777498 cites W2123137799 @default.
• W4382777498 cites W2132334298 @default.
• W4382777498 cites W2138871107 @default.
• W4382777498 cites W2142095475 @default.
• W4382777498 cites W2157869208 @default.
• W4382777498 cites W2168666423 @default.
• W4382777498 cites W2344756294 @default.
• W4382777498 cites W2750993488 @default.
• W4382777498 cites W2754271091 @default.
• W4382777498 cites W2757533499 @default.
• W4382777498 cites W2890575335 @default.
• W4382777498 cites W2896338416 @default.
• W4382777498 cites W2897924093 @default.
• W4382777498 cites W2939662940 @default.
• W4382777498 cites W2941015552 @default.
• W4382777498 cites W2958782718 @default.
• W4382777498 cites W2972058749 @default.
• W4382777498 cites W3000956463 @default.
• W4382777498 cites W3076128382 @default.
• W4382777498 cites W3183349837 @default.
• W4382777498 cites W4225403198 @default.
• W4382777498 doi "https://doi.org/10.1007/s12325-023-02565-3" @default.
• W4382777498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37391667" @default.
• W4382777498 hasPublicationYear "2023" @default.
• W4382777498 type Work @default.
• W4382777498 citedByCount "1" @default.
• W4382777498 countsByYear W43827774982023 @default.
• W4382777498 crossrefType "journal-article" @default.
• W4382777498 hasAuthorship W4382777498A5019246724 @default.
• W4382777498 hasAuthorship W4382777498A5027575751 @default.
• W4382777498 hasAuthorship W4382777498A5030667668 @default.
• W4382777498 hasAuthorship W4382777498A5035492584 @default.
• W4382777498 hasAuthorship W4382777498A5037134872 @default.
• W4382777498 hasAuthorship W4382777498A5044010028 @default.
• W4382777498 hasAuthorship W4382777498A5044597853 @default.
• W4382777498 hasAuthorship W4382777498A5052485494 @default.
• W4382777498 hasAuthorship W4382777498A5079519206 @default.
• W4382777498 hasAuthorship W4382777498A5087322552 @default.
• W4382777498 hasAuthorship W4382777498A5090203143 @default.
• W4382777498 hasBestOaLocation W43827774981 @default.
• W4382777498 hasConcept C126322002 @default.
• W4382777498 hasConcept C142724271 @default.
• W4382777498 hasConcept C16020263 @default.
• W4382777498 hasConcept C165637977 @default.
• W4382777498 hasConcept C204787440 @default.
• W4382777498 hasConcept C27081682 @default.
• W4382777498 hasConcept C2777714996 @default.
• W4382777498 hasConcept C2778341716 @default.
• W4382777498 hasConcept C2779832356 @default.
• W4382777498 hasConcept C3018587741 @default.
• W4382777498 hasConcept C55520419 @default.
• W4382777498 hasConcept C71924100 @default.
• W4382777498 hasConceptScore W4382777498C126322002 @default.
• W4382777498 hasConceptScore W4382777498C142724271 @default.
• W4382777498 hasConceptScore W4382777498C16020263 @default.
• W4382777498 hasConceptScore W4382777498C165637977 @default.
• W4382777498 hasConceptScore W4382777498C204787440 @default.
• W4382777498 hasConceptScore W4382777498C27081682 @default.
• W4382777498 hasConceptScore W4382777498C2777714996 @default.
• W4382777498 hasConceptScore W4382777498C2778341716 @default.
• W4382777498 hasConceptScore W4382777498C2779832356 @default.
• W4382777498 hasConceptScore W4382777498C3018587741 @default.
• W4382777498 hasConceptScore W4382777498C55520419 @default.
• W4382777498 hasConceptScore W4382777498C71924100 @default.
• W4382777498 hasFunder F4320309432 @default.
• W4382777498 hasIssue "9" @default.
• W4382777498 hasLocation W43827774981 @default.
• W4382777498 hasLocation W43827774982 @default.
• W4382777498 hasLocation W43827774983 @default.
• W4382777498 hasOpenAccess W4382777498 @default.
• W4382777498 hasPrimaryLocation W43827774981 @default.
• W4382777498 hasRelatedWork W1969070671 @default.
• W4382777498 hasRelatedWork W2091120910 @default.
• W4382777498 hasRelatedWork W2315538569 @default.
• W4382777498 hasRelatedWork W2340104373 @default.
• W4382777498 hasRelatedWork W2358667551 @default.

• next